Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01677780 · ClinicalTrials.gov registry record · Phase 1
An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies
A Phase 1 study of Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 5
- Study locations
NCT01677780 is a Phase 1 study of Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute that has completed, run by Hoffmann-La Roche. The registered enrollment target is 11 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT01677780, a Phase 1 study of Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 5
- Study locations
Study Summary
This open-label, extension study is designed to provide continuing treatment with RO5045337 to participants who have completed parent studies NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296). Participants are eligible to participate in this study if they have completed required Phase 1 study assessments for primary objectives of respective parent protocol and are having evidence of clinical benefit (as defined by the parent protocol). Participants will continue the most similar dose and formulation available (which does not exceed the maximum tolerated dose \[MTD\] or the maximum safely administered dose for that formulation during Phase 1) and the same schedule of RO5045337 treatment that they were receiving at the time of transitioning from the parent clinical study protocol.
Conditions Studied
Interventions
- DRUG RO5045337
Study Locations (5)
Texas
- M.D Anderson Cancer Center; Oncology - Houston
- Cancer Therapy & Research Ctr; Dept Institute for Drug Development - San Antonio
California
- Sarcoma Oncology Center - Santa Monica
Ontario
- Princess Margaret Hospital, Medical Oncology & Haematology - Toronto
Other
- Institut Claudius Regaud; Departement Oncologie Medicale - Toulouse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2012-11-28 |
| Est. Completion | 2017-06-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01677780
The ClinicalTrials.gov registry entry for NCT01677780 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute appearing as the primary indexed condition, and to 1 intervention - of which RO5045337 is the first listed.
NCT01677780 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, California, Ontario.
Frequently Asked Questions
What is clinical trial NCT01677780 about?
NCT01677780 is a clinical study titled "An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies". This open-label, extension study is designed to provide continuing treatment with RO5045337 to participants who have completed parent studies NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296). Participants are eligible to participate ...
What is the current status of trial NCT01677780?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2012-11-28. Estimated completion is 2017-06-26.
What conditions does trial NCT01677780 study?
This clinical trial studies the following conditions: Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute.
What interventions are being tested in trial NCT01677780?
The interventions under investigation include: RO5045337 (DRUG).
Who is sponsoring clinical trial NCT01677780?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01677780 being conducted?
This trial has 5 study locations across California, Texas, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.